Oruka Therapeutics (ORKA) and Its Rivals Head-To-Head Comparison

Oruka Therapeutics (NASDAQ:ORKAGet Free Report) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its competitors? We will compare Oruka Therapeutics to similar companies based on the strength of its earnings, analyst recommendations, profitability, dividends, valuation, institutional ownership and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Oruka Therapeutics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics 0 0 6 2 3.25
Oruka Therapeutics Competitors 865 812 1352 23 2.17

Oruka Therapeutics currently has a consensus price target of $43.17, indicating a potential upside of 56.17%. As a group, “Diagnostic substances” companies have a potential upside of 44.80%. Given Oruka Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Oruka Therapeutics is more favorable than its competitors.

Earnings and Valuation

This table compares Oruka Therapeutics and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Oruka Therapeutics N/A -$5.34 million -4.60
Oruka Therapeutics Competitors $550.54 million $6.13 million -106.89

Oruka Therapeutics’ competitors have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Oruka Therapeutics has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ competitors have a beta of 1.30, suggesting that their average share price is 30% more volatile than the S&P 500.

Profitability

This table compares Oruka Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oruka Therapeutics N/A -20.18% -19.51%
Oruka Therapeutics Competitors -1,887.59% -41.66% -26.54%

Summary

Oruka Therapeutics beats its competitors on 9 of the 12 factors compared.

About Oruka Therapeutics

(Get Free Report)

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.